Examiner: VAN DRUFF, SYDNEY

Tech Center 1600 • Art Units: 1643

This examiner grants 56% of resolved cases

Performance Statistics

55.6%

Allow Rate

-4.4% vs TC avg

177

Total Applications

+30.6%

Interview Lift

1140

Avg Prosecution Days

Based on 142 resolved cases, 2023–2026

3.3%

§101 Eligibility

14.3%

§102 Novelty

36.3%

§103 Obviousness

25.3%

§112 Clarity

App #	Title	Status	Assignee
18590729	SELECTIVE REDUCTION OF ANTIBODIES	Non-Final OA	AbbVie Inc.
17934996	PROTEIN NANOPARTICLES AND COMBINATION THERAPY FOR CANCER IMMUNOTHERAPY	Final Rejection	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
17775198	IDENTIFICATION OF SPLICING-DERIVED ANTIGENS FOR TREATING CANCER	Non-Final OA	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.